Characteristic | All (1,331 cycles) | Re-expasion group (1,126 cycles) | Shrinkage group (205 cycles) | P value |
---|---|---|---|---|
Age | 38.0 (22–48) | 37.0 (22–48) | 38.4 (25–48) | < 0.001 |
BMI (kg/m2) | 22.0 (0–38.6) | 21.8 (0–37.4) | 22.3 (16.9–38.6) | < 0.05 |
AMH (ng/mL) | 2.48 (0.02–46.1) | 3.2 (0–18.5) | 3.00 (0.05–17.3) | < 0.01 |
Basal FSH (mIU/mL) | 7.0 (0–31.2) | 6.9 (0–31.2) | 7.2 (0.4–25.6) | N.S |
Basal LH (mIU/mL) | 4.6 (0–14.8) | 4.6 (0–14.8) | 4.9 (0–14.5) | N.S |
Basal E2 (pg/mL) | 33.5 (0–98.4) | 33.4 (0–98.4) | 34.4 (0–92.2) | N.S |
Endometrial thickness (mm) | 9.9 (6.2–20.2) | 9.9 (6.2–20.2) | 9.8 (7.2–17.2) | N.S |
Serum E2 value on ET day (pg/mL) | 227 (10–1,745) | 224 (10–1,745) | 234 (26.7–1,585) | N.S |
Serum P4 value on ET day (ng/mL) | 12.6 (0.11–81.2) | 12.7 (1.5–81.2) | 12.8 (1.24–34.7) | N.S |
Number of natural cycles/hormone replacement therapy cycles (n) | 89/1,242 | 70/1,056 | 19/186 | N.S |
GQB (%[n]) | 75.1 (999) | 79.4 (894) | 51.2 (105) | < 0.001 |
Blastocyst shrinkage at 2–11 min after warming (%[n]) | 19.9 (265) | 7.6 (86) | 87.3 (179) | < 0.001 |
Assisted hatching (%[n]) | 89.0 (1,183) | 88.3 (993) | 93.2 (191) | < 0.05 |
Hyaluronic acid-enriched transfer medium | 2.7 (36) | 2.7 (30) | 2.9 (6) | N.S |
Infertility causes (total number of causes) | 1,484 | 1,260 | 438 | Â |
 Male factor | 514 (34.6%) | 430 (34.1%) | 84 (37.5%) | N.S |
 Tubal factor | 101 (6.8%) | 89 (7.1%) | 12 (5.4%) | N.S |
 Cervical factor | 16 (1.1%) | 15 (1.2%) | 1 (0.45%) | N.S |
 Endometriosis | 72 (4.9%) | 59 (4.7%) | 13 (5.8%) | N.S |
 Polycystic ovarian syndrome | 58 (3.9%) | 52 (4.1%) | 6 (2.7%) | N.S |
 Thyroid dysfunction | 38 (2.6%) | 34 (2.7%) | 4 (1.8%) | N.S |
 Hyperprolactinemia | 4 (0.27%) | 2 (0.16%) | 2 (0.89%) | N.S |
 Anti-sperm-antibodies | 12 (0.81%) | 12 (0.95%) | 0 (0%) | N.S |
 Uterine fibroid | 48 (3.2%) | 42 (3.3%) | 6 (2.7%) | N.S |
 Adenomyosis | 5 (0.34%) | 5 (0.40%) | 0 (0%) | N.S |
 Uterine malformation | 30 (2.0%) | 25 (2.0%) | 5 (2.2%) | N.S |
 Diminished ovarian reserve | 133 (9.0%) | 109 (8.7%) | 24 (10.7%) | N.S |
 Oncofetility | 14 (0.94%) | 14 (1.1%) | 0 (0%) | N.S |
 Unexplained infertility | 438 (29.5%) | 371 (29.4%) | 67 (29.9%) | N.S |